Background Natural infection and vaccination against SARS-CoV-2 is associated with the
development of immunity against the structural proteins of the virus. Specifically, the two …

The SARS‐CoV‐2 virus was detected for the first time in December 2019 in Wuhan, China.
Currently, this virus has spread around the world, and new variants have emerged. This new …

The first case of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), in Brazil was diagnosed on February 26, 2020. Due …

BACKGROUND: There are few studies to compare antibody response against anti-spike (S)
and anti-nucleoprotein (N) SARS-CoV-2. OBJECTIVE: The aim of this study was to evaluate …

COVID-19 is the name of the acute respiratory disease caused by the new coronavirus
SARS-CoV-2, a close relative of those that caused the severe outbreaks of SARS and MERS …

Most community-specific serological surveys for SARS-CoV-2 antibodies have been
performed in healthcare workers and institutions. In this study, IgG antibodies specific to the …

Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been approved for controlling the coronavirus disease 2019 (COVID-19) pandemic …

The immune response to SARS-CoV-2 has been extensively studied following the pandemic
outbreak in 2020; however, the presence of specific T cells against SARS-CoV-2 before …

Introduction: We evaluated the immunoglobulin (Ig) G antibody response against the
nucleocapsid protein (NP) and the receptor-binding domain (RBD) of the spike protein of …

With the development of SARS-CoV-2 vaccines, many authors started evaluating the
immunization efficacy of the available vaccines mainly through sero-positivity tests or by a …